TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

CTI BioPharma Corp (NASDAQ:CTIC) Investor Investigation Concerning Possible Breaches Of Fiduciary Dutes Announced

  • If you purchased shares of CTI BioPharma Corp (NASDAQ:CTIC) and currently hold any of those NASDAQ:CTIC shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
CTI BioPharma Corp
Security
NASDAQ: CTIC

Summary

July 14, 2014 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares CTI BioPharma Corp (NASDAQ:CTIC) shares was announced over potential breaches of fiduciary duties by certain officers and directors at CTI BioPharma, formerly Cell Therapeutics.

The investigation by a law firm concerns whether certain CTI BioPharma officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

CTI BioPharma Corp reported that its annual Total Revenue rose to $34.68 million in 2013 and that its Net Loss of $101.37 million in 2012 declined to a Net Loss of $42.74 million in 2013. Shares of CTI BioPharma Corp (NASDAQ:CTIC) grew from $1.03 per share in July 2013 to as high as $4.00 per share in January 2014. Since then NASDAQ:CTIC shares declined to $2.68 per share on July 11, 2014.

On July 11, 2014, NASDAQ:CTIC shares closed at $2.69 per share.

Start Monitoring Your Investments